RKDA (Arcadia Biosciences, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by RKDA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-14 | GREGORY D WALLER | Director | A | — | — |
| 2026-09-14 | Lilian Shackelford Murray | Director | A | — | — |
| 2026-09-14 | Amy Yoder | Director | A | — | — |
| 2026-09-14 | Kevin Comcowich | Director | A | — | — |
| 2025-05-12 | Thomas J. Schaefer | Chief Executive Officer | A | — | — |
| 2025-05-12 | Mark Kawakami | Chief Financial Officer | A | — | — |
| 2025-02-05 | Mark Kawakami | Chief Financial Officer | Buy | — | — |
| 2025-02-05 | Thomas J. Schaefer | Chief Executive Officer | Buy | — | — |
| 2024-08-21 | Thomas J. Schaefer | Chief Executive Officer | A | — | — |
| 2024-08-21 | Albert D. Bolles | Director | A | — | — |
| 2024-08-21 | Kevin Comcowich | Director | A | — | — |
| 2024-08-21 | Amy Yoder | Director | A | — | — |
| 2024-08-21 | Mark Kawakami | Chief Financial Officer | A | — | — |
| 2024-08-21 | Deborah D Carosella | Director | A | — | — |
| 2024-08-21 | Lilian Shackelford Murray | Director | A | — | — |
| 2024-08-21 | GREGORY D WALLER | Director | A | — | — |
| 2024-08-20 | Mark Kawakami | Chief Financial Officer | Buy | — | — |
| 2024-08-20 | Thomas J. Schaefer | Chief Executive Officer | Buy | — | — |
| 2024-02-05 | Thomas J. Schaefer | Chief Financial Officer | Buy | — | — |
| 2023-08-07 | Thomas J. Schaefer | Chief Financial Officer | Buy | — | — |
| 2023-06-16 | Albert D. Bolles | Director | A | — | — |
| 2023-06-16 | Amy Yoder | Director | A | — | — |
| 2023-06-16 | Deborah D Carosella | Director | A | — | — |
| 2023-06-16 | Lilian Shackelford Murray | Director | A | — | — |
| 2023-06-16 | Kevin Comcowich | Director | A | — | — |
| 2023-06-16 | GREGORY D WALLER | Director | A | — | — |
| 2023-05-30 | Stanley Jacot Jr | Chief Executive Officer | Buy | — | — |
| 2023-04-28 | LAURA PITLIK | Chief Marketing Officer | A | — | — |
| 2023-04-28 | Thomas J. Schaefer | Chief Financial Officer | A | — | — |
| 2023-04-28 | Stanley Jacot Jr | Chief Executive Officer | A | — | — |
| 2023-02-02 | Thomas J. Schaefer | Chief Financial Officer | Buy | — | — |
| 2023-01-05 | Thomas J. Schaefer | Chief Financial Officer | A | — | — |
| 2022-08-18 | LAURA PITLIK | Chief Marketing Officer | A | — | — |
| 2022-08-18 | Pamela Haley | Chief Financial Officer | A | — | — |
| 2022-08-03 | Pamela Haley | Chief Financial Officer | Buy | — | — |
| 2022-06-03 | Deborah D Carosella | Director | A | — | — |
| 2022-06-03 | Kevin Comcowich | Director | A | — | — |
| 2022-06-03 | Albert D. Bolles | Director | A | — | — |
| 2022-06-03 | Lilian Shackelford Murray | Director | A | — | — |
| 2022-06-03 | Amy Yoder | Director | A | — | — |
| 2022-06-03 | GREGORY D WALLER | Director | A | — | — |
| 2022-04-13 | LAURA PITLIK | Chief Marketing Officer | A | — | — |
| 2022-04-13 | Pamela Haley | Chief Financial Officer | A | — | — |
| 2022-02-04 | Stanley Jacot Jr | Chief Executive Officer | A | — | — |
| 2021-07-13 | LAURA PITLIK | Chief Marketing Officer | A | — | — |
| 2021-06-04 | Kevin Comcowich | Director | A | — | — |
| 2021-06-04 | Albert D. Bolles | Director | A | — | — |
| 2021-06-04 | Amy Yoder | Director | A | — | — |
| 2021-06-04 | GREGORY D WALLER | Director | A | — | — |
| 2021-06-04 | Lilian Shackelford Murray | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 25,249 | — |
| — | 10%+ Owner | 22,255 | — |
| — | 10%+ Owner | 22,255 | — |
| — | 10%+ Owner | 20,434 | — |
| — | Chief Executive Officer | 5,000 | — |
| — | Chief Executive Officer | 2,819 | — |
| — | Chief Financial Officer | 2,681 | — |
| — | Director | 500 | — |
| — | Director | 469 | — |
| — | Chief Executive Officer | 357 | — |
| — | Chief Technology Officer | 325 | — |
| — | Director | 309 | — |
| — | Director | 213 | — |
| — | Chief Financial Officer | 127 | — |
| — | Chief Commercial Officer | 95 | — |
| — | Director | 63 | — |
| — | Chief Scientific Officer | 59 | — |
| — | VP Product Development | 58 | — |
| — | Interim Chief Financ. Officer | 51 | — |
| — | VP Regulatory and Compliance | 16 | — |
| — | Chief Operating Officer | 16 | — |
| — | Director | 6 | — |
| — | VP, Chief Legal Officer | 5 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RKDA quote page; the site-wide leaderboard is on the insider transactions hub.